Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00115791 · ClinicalTrials.gov registry record · Phase 3
Study to Determine the Response and Effectiveness of RSD1235 in Subjects With Atrial Fibrillation or Atrial Flutter
A Phase 3 study of Atrial Fibrillation and Atrial Flutter, sponsored by Astellas Pharma.
- Completed
- Registry status
- Phase 3
- Development phase
- 276
- Enrollment target
- 20
- Study locations
NCT00115791: Completed Phase 3 study of Atrial Fibrillation and Atrial Flutter, sponsored by Astellas Pharma.
NCT00115791 is a Phase 3 study of Atrial Fibrillation and Atrial Flutter that has completed, run by Astellas Pharma. The registered enrollment target is 276 participants, below the 2,996-participant average among 202 other Atrial Fibrillation trials with a reported enrollment target (91% lower). The trial reports 20 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00115791, a Phase 3 study of Atrial Fibrillation and Atrial Flutter, has completed, sponsored by Astellas Pharma.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 276 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to demonstrate the effectiveness of RSD1235 compared with placebo, in the conversion of atrial fibrillation or atrial flutter to sinus rhythm.
Conditions Studied
Interventions
- DRUG placebo
- DRUG RSD1235
Study Locations (20)
Florida
- Investigative Site - Gainesville
- Investigative Site - Orlando
- Investigative Site - Port Charlotte
Alabama
- Investigative Site - Birmingham
- Investigative Site - Huntsville
Michigan
- Investigative Site - Lansing
- Investigative Site - Petoskey
Texas
- Investigative Site - Amarillo
- Investigative Site - Houston
Indiana
- Investigative Site - Indianapolis
Louisiana
- Investigative Site - Shreveport
Maryland
- Investigative Site - Baltimore
Minnesota
- Investigative Site - Saint Paul
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 276 participants |
| Start Date | 2004-06 |
| Est. Completion | 2005-06 |
| Phase | Phase 3 |
What the finished NCT00115791 record still lists
NCT00115791 is an interventional study that assigns participants to a tested intervention. The registered 276 participants enrollment target is mid-sized for trials with a published cap, below the 2,996-participant average among 202 other Atrial Fibrillation trials with a reported enrollment target (91% lower).
The record links to 2 conditions, with Atrial Fibrillation appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.
NCT00115791 names 20 study sites across 15 states, led by Florida, Alabama, Michigan.
Frequently Asked Questions
What is clinical trial NCT00115791 about?
NCT00115791 is a clinical study titled "Study to Determine the Response and Effectiveness of RSD1235 in Subjects With Atrial Fibrillation or Atrial Flutter". The purpose of this study is to demonstrate the effectiveness of RSD1235 compared with placebo, in the conversion of atrial fibrillation or atrial flutter to sinus rhythm.
What is the current status of trial NCT00115791?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 276 participants. The study started on 2004-06. Estimated completion is 2005-06.
What conditions does trial NCT00115791 study?
This clinical trial studies the following conditions: Atrial Fibrillation, Atrial Flutter.
What interventions are being tested in trial NCT00115791?
The interventions under investigation include: placebo (DRUG), RSD1235 (DRUG).
Who is sponsoring clinical trial NCT00115791?
This trial is sponsored by Astellas Pharma, which has 165 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00115791 being conducted?
This trial has 20 study locations across Alabama, Florida, Indiana, Louisiana, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atrial Fibrillation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00115791's enrollment target sits among peer trials
276 84th of 202 higher than 118 of 202 other Atrial Fibrillation trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Atrial Fibrillation trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
The Rhythm Evaluation for AntiCoagulaTion With Continuous Monitoring of Atrial Fibrillation
RECRUITING · Phase 3
-
Comparing Magnesium 2g Versus 4g Versus Placebo in the Incidence of Treating AFF RVR
RECRUITING · Phase 3
-
Anticoagulation in ICH Survivors for Stroke Prevention and Recovery
RECRUITING · Phase 3
-
Semaglutide for Metabolic Intervention and Adipose Loss to Treat Atrial Fibrillation
RECRUITING · Phase 3
-
Dapagliflozin in Patients With Atrial Fibrillation (DAPA-AF)
RECRUITING · Phase 3
-
Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01371630 · 276 participants · Phase 1
Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia
- NCT04192344 · 276 participants · Phase 1
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK-021 in Patients With Advanced Solid Tumor
- NCT05294991 · 276 participants · NA
Wellness App for Sleep Disturbance in Hematological Cancer Patients
- NCT05610852 · 276 participants · NA
Single-Port Transvesical Partial Prostatectomy Versus High Intensity Focused Ultrasound
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia